Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Traws Pharma, Inc. - Common Stock (NQ:TRAW)

1.325 +0.115 (+9.50%)
Streaming Delayed Price Updated: 2:28 PM EDT, Apr 29, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 547,846
Open 1.410
Bid (Size) 1.300 (800)
Ask (Size) 1.350 (1,100)
Prev. Close 1.210
Today's Range 1.250 - 1.430
52wk Range 0.9700 - 3.265
Shares Outstanding 5,564,315
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
TRAWS PHARMA INC (NASDAQ:TRAW) Reports 2025 Earnings Beat Amid Dilutive $60M PIPE Financing and FDA Hold ↗
Traws Pharma reports 2025 net income but stock falls on dilutive $60M PIPE financing. Focus remains on clinical trials for its influenza and COVID-19 antiviral candidates. 
Via Chartmill
Topics Earnings
News headline image
Traws Pharma Reports Full Year 2025 Results and Provides Business Highlights
From Traws Pharma, Inc.
Via GlobeNewswire

Performance

YTD
-0.4%
-0.4%
1 Month
-24.3%
-24.3%
3 Month
-53.0%
-53.0%
6 Month
-48.4%
-48.4%
1 Year
-12.8%
-12.8%

More News

Read More
News headline image
Traws Pharma Announces Up to $60 Million Private Placement Financing
From Traws Pharma, Inc.
Via GlobeNewswire
Top stock movements in today's session. ↗
Via Chartmill
TRAW Stock Slides In Volatile Session –  What’s The Latest On Its Phase 2 Trial For COVID-19 Treatment? ↗
Via Stocktwits
Gapping stocks in Thursday's session ↗
Via Chartmill
Stay updated with the stocks that are on the move in today's pre-market session. ↗
Via Chartmill
News headline image
Traws Pharma Completes Analysis of Ratutrelvir Clinical Study in PAXLOVID®-Eligible and Ineligible COVID-19 Patients and Provides Updates for Additional Indication for Tivoxavir Marboxil as a Prophylactic Treatment for Seasonal Influenza
From Traws Pharma, Inc.
Via GlobeNewswire
Top movers analysis in the middle of the day on 2026-01-28: top gainers and losers in today's session. ↗
Via Chartmill
News headline image
Traws Pharma Completes Enrollment of Ratutrelvir Clinical Study in PAXLOVID®-Eligible and Ineligible COVID-19 Patients; Announces Plans for Added Indication for Tivoxavir Marboxil as a Prophylactic Treatment for Seasonal Influenza
From Traws Pharma, Inc.
Via GlobeNewswire
News headline image
Traws Pharma Files Tivoxavir Marboxil Investigational New Drug (IND) Application for Influenza Therapy, and Provides Updated Results from the Ongoing Clinical Study of Ratutrelvir in PAXLOVID®-Eligible and Ineligible COVID-19 Patients
From Traws Pharma, Inc.
Via GlobeNewswire
News headline image
Let's have a look at the top gainers and losers one hour before the close of the markets of today's session. ↗
Via Chartmill
News headline image
Traws Pharma Reports Positive Interim Clinical Data with Ratutrelvir Versus PAXLOVID™, Shows Activity in PAXLOVID-Ineligible COVID-19 Patients
From Traws Pharma, Inc.
Via GlobeNewswire
News headline image
Top movers analysis one hour before the close of the markets on 2025-11-14: top gainers and losers in today's session. ↗
Via Chartmill
News headline image
Which stocks are moving on Friday? ↗
Via Chartmill
News headline image
12 Health Care Stocks Moving In Friday's Intraday Session ↗
Via Benzinga
News headline image
Traws Pharma Reports Third Quarter 2025 Results and Business Highlights
From Traws Pharma, Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Monday's After-Market Session ↗
Via Benzinga
News headline image
Traws Pharma Doses First Patient with Ratutrelvir in Phase 2 COVID Studies, Expects Results by Year-End 2025
From Traws Pharma, Inc.
Via GlobeNewswire
News headline image
Traws Pharma Adds John Leaman, MD, as Independent Director and Formalizes Appointments of Two Key Executives
From Traws Pharma, Inc.
Via GlobeNewswire
BioMedNewsBreaks — Annovis Bio Inc. (NYSE: ANVS) Appoints Mark Guerin as Chief Financial Officer
Via Investor Brand Network
News headline image
Annovis Appoints Mark Guerin as Chief Financial Officer
From Annovis Bio Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗
Via Benzinga
News headline image
12 Health Care Stocks Moving In Friday's Pre-Market Session ↗
Via Benzinga
News headline image
Traws Pharma Receives Approval to Proceed with Phase 2 COVID Studies with Ratutrelvir, Expects Results by Year-End 2025
From Traws Pharma, Inc.
Via GlobeNewswire

Frequently Asked Questions

Is Traws Pharma, Inc. - Common Stock publicly traded?
Yes, Traws Pharma, Inc. - Common Stock is publicly traded.
What exchange does Traws Pharma, Inc. - Common Stock trade on?
Traws Pharma, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Traws Pharma, Inc. - Common Stock?
The ticker symbol for Traws Pharma, Inc. - Common Stock is TRAW on the Nasdaq Stock Market
What is the current price of Traws Pharma, Inc. - Common Stock?
The current price of Traws Pharma, Inc. - Common Stock is 1.325
When was Traws Pharma, Inc. - Common Stock last traded?
The last trade of Traws Pharma, Inc. - Common Stock was at 04/29/26 02:28 PM ET
What is the market capitalization of Traws Pharma, Inc. - Common Stock?
The market capitalization of Traws Pharma, Inc. - Common Stock is 7.37M
How many shares of Traws Pharma, Inc. - Common Stock are outstanding?
Traws Pharma, Inc. - Common Stock has 7M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.